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ABSTRACT
Adrenomedullin (AM) is a multifunctional peptide vasodilator
that signals through a G-protein-coupled receptor when the
receptor, called calcitonin receptor-like receptor (CL), is
associated with a receptor activity-modifying protein 2
(RAMP2). We demonstrated previously that haploinsufficieny
for each of these genes led to reduced maternal fertility, and that
even a modest genetic reduction of AM peptide caused maternal
defects in implantation, placentation, and fetal growth. Here, we
further demonstrate that Admþ/ female mice displayed reduced
pregnancy success rates that were not caused by defects in
folliculogenesis, ovulation, or fertilization. The poor fertility of
Admþ/ female mice could not be rescued by transfer of wild-
type blastocysts, which suggested an underlying defect in uterine
receptivity. In fact, we found that Adm, Calcrl, and Ramp2 gene
expressions are tightly and spatiotemporally regulated in the
luminal epithelial cells of the uterus during the estrus cycle and
the peri-implantation period. RAMP3, which also generates an
AM receptor when associated with CL, had a diametrically
opposite expression pattern than that of Adm, Calcrl, and Ramp2
and was most robustly induced in the stroma of the uterus.
Finally, we discovered that Admþ/ female mice have a
substantially reduced number of pinopodes on the uterine
luminal epithelial surface, which is indicative and possibly
causative of the poor uterine receptivity. Taken together, our
studies identify a new class of pharmacologically tractable
proteins that are involved in establishing uterine receptivity
through the regulation of pinopode formation.
adrenomedullin, female fertility, female reproductive tract, gene-
targeted mouse models, gene targeting, implantation, pinopodes,
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INTRODUCTION
It is widely accepted that tightly controlled molecular cues
from both the maternal endometrium and the preimplanting
blastocyst are required for establishing a normal pregnancy. A
precisely orchestrated maternal-fetal dialogue driven by
maternal hormones leads to the expression and secretion of
growth factors, vasodilators, adhesion molecules, and innate
immune response factors that are required for the attachment
and invasion of the blastocyst to the uterine epithelium [1].
Although studies in rodent and primate models have uncovered
a multitude of gene products implicated in the normal growth
and development of the early blastocyst, remarkably fewer
genes have been shown to have a causal role in the
establishment of a receptive uterus. As a consequence, there
are few clinically useful biomarkers for diagnosing or
potentially treating a nonreceptive uterus in human patients
with infertility [2].
Adrenomedullin (AM) is a 52-amino acid peptide vasodilator
that circulates in the plasma and can influence many biological
processes [3]. The gene coding for AM peptide, Adm, is widely
expressed throughout the body and is most robust in endothelial
cells and vascular smooth muscle cells [4]. Consequently,
highly vascularized tissues, such as the placenta and uterus,
produce high levels of AM peptide [5, 6]. Adrenomedullin
transduces its biological activity by binding to a G-protein-
coupled receptor, calcitonin receptor-like receptor (CL for
protein, Calcrl for gene), when the receptor is associated with a
single-transmembrane accessory protein called receptor activi-
ty-modifying protein 2 (RAMP2) [7]. Interestingly, pharmaco-
logical studies have also demonstrated high affinity for AM
binding when CL is associated with RAMP3, but the
physiological significance of this interaction remains unknown
[8]. Therefore, careful evaluation of the coexpression of Calcrl
as well as the Ramp2 and Ramp3 genes is required to define the
tissues and cells in which AM can transduce its signal through
an autocrine or paracrine mode of action.
The genes that encode for AM and its receptor components are
highly expressed in the human and rodent uterus under the direct
control of estrogen and progesterone [6, 9–14]. Transcriptional
profiling of wild-type and estrogen receptor knockout mice
revealed that Ramp3 was one of the most highly estrogen-induced
genes in the uterus [15, 16], and other studies using chromatin
immunoprecipitation assays have shown a direct association
between the estrogen receptor and transcriptional regulatory
elements of both the Adm and Ramp3 genes [16]. Taken together,
these gene expression studies suggest that hormonal regulation of
AM signaling in the uterus during the estrus cycle and pregnancy
may play important physiological roles.
Numerous studies in humans and experimental animal
models have supported an important role for AM signaling
during pregnancy [17, 18]. In humans, maternal plasma levels
of AM rise throughout gestation and eventually peak to four to
five times over prepregnancy values before returning to basal
levels 24 h after delivery [19–23]. It has been widely speculated
that during complications of pregnancy, like preeclampsia,
gestational diabetes, small for gestational age infants, and
spontaneous abortions, altered levels of maternal AM may be
indicative of the condition and/or even contribute to poor
reproductive outcomes [24–30]. Our previous studies using
genetically engineered mice heterozygous for deletion of the
Adm gene have supported an essential role for AM during
pregnancy. Although Adm/ mice are embryonic lethal, we
found that pregnant Admþ/ mice displayed abnormal implan-
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tation, uterine overcrowding, and placental abnormalities,
resulting in fetal growth restriction that was largely independent
of the genotype of the embryo [31]. Therefore, even a modest
reduction in maternal Adm gene expression caused profound
defects in the implantation and placentation processes.
During the course of these previous studies, we also noticed
that Admþ/ female mice appeared to have significantly lower
success rates for establishing a pregnancy following a
successful mating. Here, we describe in more detail the
apparent cause for poor reproductive outcomes preceding
implantation in Admþ/ female mice.
MATERIALS AND METHODS
Mice
Generation of mice with a targeted deletion of the Adm gene has been
described previously [32]. We and others historically and commonly refer to
the Adm gene-targeted allele as AMþ/, and so we emphasize that the
nomenclature used in the current study does not describe a new allele, but
rather conforms to established nomenclature rules. The Admþ/ line is
maintained as a heterozygote breeding colony on an isogenic 129S6/SvEv
background. Genotyping was performed by a three-primer, PCR-based
strategy: primer 1, 50-CAGTGAGGAATGCTAGCCTC-3 0; primer 2, 50-
GCTTCCTCTTGCAAAACCACA-30; and primer 3, 50-TCGAGCTTCCAAG-
GAAGACCAGG-30. Primers 1 and 3 amplified a 1.8-kb wild-type product,
whereas primers 2 and 3 amplified a 1.3-kb targeted product. Unless otherwise
stated, experimental and control animals were strain and age matched. For
timed pregnancies, Admþ/ or wild-type 129S6/SvEv breedings were
established, and the day when the vaginal plug was detected was considered
Embryonic Day 0.5 (Day E0.5). Scoring of successful pregnancies following
detection of a vaginal plug was evaluated either at Day E9.5 (postimplantation)
or Postnatal Day 1. All experiments were approved by the Institutional Animal
Care and Use Committee of The University of North Carolina at Chapel Hill.
Ovulation, Superovulation, and Fertilization Assay
Natural matings of one wild-type male with two wild-type females or two
Admþ/ females were established. On Day E1.5, females were euthanized and
oviducts were flushed with M2 medium (M7167; Sigma). Two-cell-stage
embryos and degenerated oocytes were counted. For superovulation, wild-type
or Admþ/ female mice were injected intraperitoneally with 5 IU eCG (G4527;
Sigma) and 44 h later with 5 IU hCG (C8554; Sigma). Mating pairs were
established, and embryos were flushed from the oviducts at Day E1.5 as
described above.
Blastocyst Transfer
The 3.5-day-old blastocysts were collected from the uteri of superovulated
C57BL/6 donor female mice purchased from Harlan. A total of 14–16
blastocysts were transferred into the uteri of 8- to 12-wk-old Admþ/ females or
wild-type recipient females anesthetized with avertin (0.5 mg/g body weight) at
Pseudopregnant Day E3.5. In breedings with vasectomized males, the morning
of the vaginal plug was designated as Day E0.5. Recipient females were
euthanized 5 days later, and the number of implanted blastocysts in the
pregnant mice was calculated.
In Situ Hybridization
Wild-type 129S6/SvEv female mice at various stages of the estrus cycle or
at Days E0.5, E2.5, or E5.5 were euthanized. Uteri were fixed in 4%
paraformaldehyde overnight and 30% sucrose in diethylpyrocarbonate-PBS
overnight and serially cryosectioned (20 lm). Sense and antisense RNA probes
were synthesized from plasmids containing cDNA sequences of the murine
Adm, Calcrl, Ramp2, or Ramp3 genes. Nonradioactive in situ hybridization
reagents were used (1745816, 1585762, and 1093274; Roche Diagnostics).
Following prehybridization, sections were hybridized to digoxigenin-labeled
sense or antisense RNA probes for 12–16 h at 608C. After washing, the sections
were incubated with anti-digoxigenin Fab-AP diluted 1:2000 in blocking buffer
at room temperature for 2 h. After washing, the sections were developed in
nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate solution in the
dark overnight, then rinsed several times in PBS at room temperature and
mounted. Sections hybridized with the sense probe served as negative controls
and showed little to no positive signal. Photos were taken with Nikon
Microphot-FXA microscope.
Scanning Electron Microscopy of Day E4.5 Mouse Uteri
Day E4.5 mouse uteri were dissected, cut open longitudinally, and pinned
to a silicone rubber mat to expose the uterine luminal epithelium. The uteri
were rinsed gently with PBS to remove surface debris and covered with a
fixative containing 2% paraformaldehyde/2.5% glutaraldehyde/0.15 M Karls-
son and Schultz sodium phosphate buffer, pH 7.4. Samples were stored at 48C
overnight to several days before processing. After several rinses in buffer, the
samples were dehydrated through an increasing series of ethanol (30%, 50%,
75%, 90%, 100%, and 100%) and dried using a Balzers CPD 020 critical point
dryer (Balzers Union Ltd.) using liquid carbon dioxide as the transition
solvent. The uteri were mounted onto aluminum scanning electron microscopy
stubs with colloidal silver paste and were sputter coated with gold:palladium
alloy (60:40) to a thickness of 20 nm using a Hummer X Sputter Coater
(Anatech Ltd., Alexandria, VA). Specimens were viewed and photographed
with a Cambridge Stereoscan S200 scanning electron microscope (LEO
Electron Microscopy Inc., Thornwood, NY) using an accelerating voltage of
20 kV.
Statistics
Statistical analyses were performed with JMP software (SAS Institute).
One-way ANOVA was used to determine significance at P , 0.05. In all
figures, error bars represent SEM.
RESULTS
Genetic Reduction of AM Causes Low Pregnancy
Success Rates
Based on our previous difficulties in maintaining a large and
robust colony of Admþ/ mice, we speculated that the rate of
successful pregnancies might be much lower for Admþ/
females than their isogenic wild-type control littermates. To
directly address this hypothesis, we scored the number of
successful pregnancies beyond implantation that resulted from
natural matings in which visualization of a vaginal plug was
evident the morning after mating. As shown in Figure 1, the
pregnancy success rate for wild-type 129S6/SvEv female mice
was 89%, whereas only 63% of the Admþ/ females with
vaginal plugs resulted in successful pregnancies. Therefore,
although our previous studies have shown clearly that maternal
genetic reduction of AM signaling leads to abnormal
implantation and placentation, these data further demonstrate
that genetic dosage of AM is also crucial to establishing a
pregnancy before implantation.
FIG. 1. Reduced pregnancy success rates in Admþ/ female mice.
Percentage of female mice that had successful pregnancies beyond
implantation following visualization of a vaginal plug. The number at the
bottom of the bars denotes the total number of female mice with an
observed vaginal plug. WT, Wild-type.
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Admþ/ Female Mice Exhibit Normal Ovulation
and Fertilization Rates
To determine whether the reduced pregnancy success rates
of Admþ/ females could be caused by defects in folliculo-
genesis or corpus luteum formation, we compared the ovaries
of Admþ/ females to those of wild-type controls. Histological
examination did not reveal any significant differences between
the two genotypes (Fig. 2). Specifically, the Admþ/ ovaries
appeared normal in size and contained follicles at all stages of
development, as well as corpus lutea.
To determine whether Admþ/ female mice had a reduction
in ovulation rates, we established natural timed matings with
wild-type males and collected oocytes from the oviduct at Day
1.5 of pregnancy. Our ability to recover oocytes from the
oviducts of plug-positive females was equivalent in both wild-
type (90%) and Admþ/ (82%) females (Fig. 3A). Moreover,
the total number of oocytes recovered from the two groups was
roughly equivalent (54 oocytes from nine wild-type females
compared with 44 oocytes from nine Admþ/ females).
Consistent with the normal ovarian histology, these data
demonstrate that mating and overall ovulation rates were not
significantly affected by genetic reduction of Admþ/.
To determine whether fertilization could occur normally in
Admþ/ females independently of endogenous hormonal
regulation, we used gonadotropin stimulation to drive super-
ovulation and compared the total number of released oocytes
and fertilized eggs to that of similarly treated wild-type
females. As shown in Figure 3B, the total number of released
oocytes, as well as fertilized eggs, did not differ between wild-
type and Admþ/ females. Taken together, these results
demonstrate that follicular development, ovulation, and
fertilization were not significantly impaired in the Admþ/
mice, and suggest that abnormal uterine receptivity may
underlie the low pregnancy success rates.
Transfer of Wild-Type Blastocysts to Admþ/ Mice Fails
to Rescue Low Pregnancy Success Rates
To evaluate whether uterine receptivity was altered in
Admþ/ females, we next performed blastocyst transfer
experiments using wild-type blastocysts from donor females
transferred into either wild-type or Admþ/ females. As shown
in Figure 4, 70% of wild-type females receiving wild-type
donor blastocytsts resulted in successful pregnancies beyond
implantation. However, only 30% of the Admþ/ females were
able to maintain a pregnancy beyond implantation with wild-
type blastocysts. These results demonstrate that maternal
genetic reduction of AM caused defects in uterine receptivity.
AM and Its Receptor Components Are Dynamically
Expressed in the Cycling Uterus
To provide a comprehensive assessment of the localization
and level of expression of Adm, Calcrl, Ramp2, and Ramp3 in
FIG. 2. Ovarian histology of Admþ/ mice appears normal. Hematox-
ylin-eosin stains of ovary sections from wild-type (WT) and Admþ/ mice
do not reveal any overt defects in folliculogenesis or corpus luteum
formation. Original magnification 340.
FIG. 3. Ovulation rates and fertilization occur normally in Admþ/
female mice. A) Percentage of female mice from which oocytes were
collected in the oviduct 1.5 days after natural mating (e1.5). B) Average
number of recovered eggs, total and fertilized, from wild-type and Admþ/
female mice following superovulation. The numbers at the bottom of the
bars represent N. WT, Wild-type.
FIG. 4. Reduced uterine receptivity in Admþ/ female mice. Transfer of
wild-type blastocysts into wild-type females (WT) resulted in successful
pregnancies in 7 of 10 mice. In contrast, only 3 of 10 Admþ/ female mice
resulted in successful pregnancies following wild-type blastocyst transfers.
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the mouse uterus during the estrus cycle, we performed in situ
hybridization. As shown in Figure 5, there was diffuse staining
for Adm in the stroma at proestrus and estrus, but the highest
levels of Adm expression were observed in the luminal
epithelial cells and somewhat lower in the glandular epitheli-
um. The expression of Adm then declined dramatically
throughout the uterus during metestrus and diestrus. Colocal-
ization of Adm expression with its receptor components, Calcrl
and Ramp2, was observed in proestrus and estrus. Notably, the
expression of Ramp2 was remarkably higher in the luminal
epithelial cells of the estrus phase than in any other phase of the
estrus cycle. Calcrl and Ramp2 expression persisted in the
luminal epithelium at metestrus and then dynamically switched
to the glandular epithelium and vasculature at diestrus. Ramp3,
which if coexpressed with Calcrl can also generate an AM
receptor, had a remarkably contrasting expression pattern to
that of Adm, Calcrl, and Ramp2. As shown in the bottom row
of Figure 5, Ramp3 was potently induced at estrus but was
spatially restricted to the first several cell layers of the
underlying stroma and was completely absent in the luminal
epithelium, where Adm, Calcrl, and Ramp2 gene expressions
were found to be most robust. Taken together, these data
indicate that genes that confer AM signaling are dynamically
expressed in a spatiotemporally regulated manner in the uterus
during the estrus cycle. The highest and most colocalized site
of expression was found on the luminal epithelial cells during
proestrus and estrus.
AM and Its Receptor Components Are Robustly Increased
Prior to the Uterine Receptive Phase
At Day 0.5 of pregnancy, before the blastocyst has attached
to the luminal epithelium of the uterus, we noticed a
remarkable induction of Adm gene expression in the luminal
epithelial cells of the uterus (Fig. 6). Although substantially
weaker than Adm, the expressions of Calcrl and Ramp2 also
were evident in the luminal epithelial layer. Adm, Calcrl, and
Ramp2 all exhibited moderate expression in the stroma at Day
E0.5 of pregnancy. In contrast, Ramp3 expression was highly
expressed in the stroma at Day E0.5. In situ hybridization of
pregnant uteri at Day E2.5 of pregnancy revealed similar
staining patterns as E0.5; however, expression of all genes in
FIG. 5. In situ hybridization of Adm and its receptor components during the uterine estrus cycle. In situ hybridization reveals that Adm, Calcrl, and
Ramp2 are coordinately expressed in uterine luminal epithelial cells at estrus, whereas Ramp3 expression is restricted to the stroma. Scale bars are
applicable to all images within a column.
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the glandular epithelium and stroma was markedly enhanced
by Day E2.5. Finally, at Day E5.5 we found that the expression
of Adm was highly upregulated in the maternal PDZ domain
(the first few underlying layers of stromal tissue surrounding
the conceptus). The expressions of Calcrl and Ramp2 were
most abundant in endothelial cords of the developing decidua
but not in the PDZ domain. Ramp3 also was expressed in
endothelial cords of the decidua, but it was robustly expressed
in the underlying stroma adjacent to the conceptus. These data
support previous studies demonstrating an increase in Adm
expression during pregnancy and highlight the dynamic and
robust changes in AM signaling that occur locally within the
receptive uterus.
Uterine Pinopodes Are Remarkably Reduced in Admþ/
Female Mice
Thus far, we demonstrated that genetic reduction of AM
caused low pregnancy success rates due to poor uterine
receptivity and that genetic components of AM signaling were
spatiotemporally regulated in the uterus during the estrus cycle
and the peri-implantation period. We next wanted to determine
whether biological markers of uterine receptivity were altered
in Admþ/ female mice. In rodents, the presence of uterine
pinopodes serves as a faithful indication of uterine receptivity.
Thus, we used scanning electron microscopy to determine
whether Admþ/ females had normal pinopode formation
during implantation. As shown in Figure 7, wild-type mice had
abundant and large plasma membrane projections of ;3
microns in diameter along the apical surface of the uterine
FIG. 6. In situ hybridization of Adm and its
receptor components during the peri-im-
plantation phase. In situ hybridization of the
uterus at Days E0.5, E2.5, and E5.5 of
pregnancy reveals that Adm, Calcrl, and
Ramp2 are highly upregulated in uterine
luminal epithelial cells. By Day E2.5 the
expression of all genes becomes apparent in
the stroma and glandular epithelium. Inset
images at Day E2.5 show sense control
probes. At Day E5.5, the expression of Adm
is very strong in the first few cell layers
surrounding the implanted conceptus,
whereas the expression of Calcrl and
Ramp2 is mostly localized to endothelial
cell cords of the decidua. Scale bars are
applicable to all images within a column.
Insets were imaged with 2.53 objective.
FIG. 7. Admþ/ female mice have reduced pinopode formation.
Scanning electron micrographs of the luminal surface of the uterus at
Day E4.5 of pregnancy. Wild-type (WT) mice show robust and evenly
distributed coverage of the luminal epithelium with ;3-lm membrane
projections called pinopodes. Admþ/ female mice had very few to no
pinopodes present throughout the uterus. Much smaller (,1 lm)
membrane blebs were sometimes found protruding from the epithelial
surface, but rarely reached the size or density of pinopodes seen in wild-
type mice.
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epithelium. In contrast, we rarely observed pinopodes in
Admþ/ females. The presence of a few pinopode-like
projections confirmed that the process of pinopode formation
was not entirely defective in Admþ/ female mice. However,
the unusually small number of pinopodes, which often were
surrounded by smaller plasma membrane blebs, demonstrated
that appropriate genetic dosage of AM may be required for
pinopode formation in the epithelium.
DISCUSSION
The major finding of our current study was that female
Admþ/ mice with a modest genetic reduction of AM peptide
had reduced pregnancy success rates due to poor uterine
receptivity. The poor uterine receptivity in Admþ/ female mice
was most remarkably illustrated by reduction in uterine
pinopodes during the preimplantation stage. The actual
function of uterine pinopodes (also referred to as uterodomes
in humans [33]) remains unclear [34], but some researchers
suggest that they allow for reorganization of the epithelial cell
surface, which in turn reduces the nonadherent glycocalyx
coating of the uterus [35]. Others have suggested that
pinopodes, as their name implies, may serve as cellular
projections that engulf relatively large volumes of fluid from
the uterine lumen [36]. We do not yet know whether there
exists a direct causal link between haploinsufficieny for AM
peptide and reduced pinopode formation in the uterine luminal
epithelial cells of Admþ/ female mice. However, it is
intriguing to speculate that AM peptide, which can potently
regulate the permeability of endothelial cells through reorga-
nization of the cellular cytoskeleton [37], may have also
acquired important roles in mediating epithelial cellular fluid
balance by influencing pinopode formation.
A few other studies using gene knockout mice with reduced
fertility or abnormal uterine receptivity have shown reduced
pinopode formation. For example, female mice that are
homozygous null for either Lif or Hoxa10 display maternally
dependant failure of implantation or decidualization, respec-
tively, which are apparently associated with reduced pinopode
formation [38, 39], although these findings have been
contested recently by others [40]. Therefore, to our knowledge
this is the first report that haploinsufficiency of a gene product
can lead to reduction in pinopode formation. Hence, our studies
emphasize the critical importance of tightly regulating the
expression and dosage of AM signaling during pregnancy.
Our study also demonstrates that the expression of AM
receptor components is equivalently dynamically regulated in
uterine tissue during the estrus cycle, receptive phase, and
implantation. Due to the lack of robust antibodies for the
murine proteins, our study was limited to addressing the
spatiotemporal expression of the genes that encode for AM,
CL, RAMP2, and RAMP3. Although our findings await
confirmation of protein distribution, we convincingly found
that Calcrl and Ramp2 were spatiotemporally colocalized with
AM peptide in most phases of the uterus. We also observed a
remarkable dichotomy between the expression patterns of
Ramp2 and Ramp3. Consistent with our findings, several
groups have shown previously that Ramp3, which contains
functional estrogen receptor DNA-binding sites in its promoter,
is one of the most potently estrogen-induced genes in the uterus
[15, 16]. However, the spatial localization of Ramp3 to the
stroma, where Calcrl and Adm were consistently low, might
suggest that the biological function of RAMP3 in the uterus
involves other, as yet unidentified G-protein-coupled receptors.
In support of this hypothesis is our finding that Calcrlþ/ and
Ramp2þ/ female mice exhibit reduced fertility similarly to
Adm
þ/ mice, but female mice that are homozygous null for
Ramp3 appear to have normal litter sizes [41]. Nevertheless,
the identification and functional validation of a conserved
signaling paradigm involving AM, CL, and RAMP2 in uterine
epithelial cells and stroma offers a unique and pharmacolog-
ically tractable system for potentially modulating uterine
receptivity.
Pinpointing the precise biological function of AM in the
uterus remains complex. The hallmark function of AM peptide
is to induce potent relaxation of vascular smooth muscle cells,
and so one obvious role for AM in the peri-implantation period
might be to induce vasodilation in order to increase blood flow
to the implantation site. However, in conflict with this notion is
our current finding that the most robust induction of AM and
its receptors during the estrus cycle and the peri-implantation
phase occurred in uterine luminal epithelial cells, rather than
vascular smooth muscle cells of the blood vasculature.
Adrenomedullin peptide also acts as an angiogenic factor,
and our recent studies in knockout mice have demonstrated that
AM signaling is required for the development of the lymphatic
vascular system [42]. Therefore, increased levels of AM
signaling at the implantation site may help drive placental
angiogenesis. Finally, it should be noted that the AM-binding
protein (AMBP-1) is also known as complement factor H, a
negative regulator of the complement activation cascade and
innate immune response [43]. So, the production and secretion
of AM during the peri-implantation period, in connection to its
interaction with an innate immune regulator, may be involved
in downregulating the maternal innate immune response to
fetal implantation. Of course, the actual role of AM in the
uterus may incorporate all of these functions, and future studies
using in vivo replacement strategies or genetically engineered
mouse models should continue to elucidate these roles.
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